[go: up one dir, main page]

MA34130B1 - Formulations pharmaceutiques solides de ramipril et de bésylate d'amlodipine et leur préparation - Google Patents

Formulations pharmaceutiques solides de ramipril et de bésylate d'amlodipine et leur préparation

Info

Publication number
MA34130B1
MA34130B1 MA35197A MA35197A MA34130B1 MA 34130 B1 MA34130 B1 MA 34130B1 MA 35197 A MA35197 A MA 35197A MA 35197 A MA35197 A MA 35197A MA 34130 B1 MA34130 B1 MA 34130B1
Authority
MA
Morocco
Prior art keywords
ramipril
preparation
amlodipine besylate
pharmaceutical formulations
solid pharmaceutical
Prior art date
Application number
MA35197A
Other languages
English (en)
Inventor
Nilesh Jaiswal
Praveen Khullar
Amol Kulkarni
Dilip Prajapati
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42786564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34130(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MA34130B1 publication Critical patent/MA34130B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B3/04—Methods of, or means for, filling the material into the containers or receptacles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D11/00—Containers having bodies formed by interconnecting or uniting two or more rigid, or substantially rigid, components made wholly or mainly of plastics material
    • B65D11/20—Details of walls made of plastics material

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mechanical Engineering (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention porte sur des compositions pharmaceutiques stables solides à dose fixée comprenant du ramipril, du bésylate d'amlodipine et des excipients pharmaceutiquement acceptables et sur leur préparation.
MA35197A 2010-02-24 2010-04-14 Formulations pharmaceutiques solides de ramipril et de bésylate d'amlodipine et leur préparation MA34130B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN417DE2010 2010-02-24
PCT/IB2010/051616 WO2011104588A2 (fr) 2010-02-24 2010-04-14 Formulations pharmaceutiques solides de ramipril et de bésylate d'amlodipine et leur préparation

Publications (1)

Publication Number Publication Date
MA34130B1 true MA34130B1 (fr) 2013-04-03

Family

ID=42786564

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35197A MA34130B1 (fr) 2010-02-24 2010-04-14 Formulations pharmaceutiques solides de ramipril et de bésylate d'amlodipine et leur préparation

Country Status (29)

Country Link
US (1) US20130146496A1 (fr)
EP (1) EP2538924B1 (fr)
JP (1) JP5719385B2 (fr)
KR (1) KR20120130761A (fr)
CN (1) CN102781430B (fr)
AR (1) AR080256A1 (fr)
AU (1) AU2010346977A1 (fr)
BR (1) BR112012021203A2 (fr)
CA (1) CA2790817A1 (fr)
CL (1) CL2012002341A1 (fr)
CR (1) CR20120432A (fr)
EA (1) EA201290817A1 (fr)
EC (1) ECSP12012121A (fr)
ES (1) ES2483154T3 (fr)
GT (1) GT201200248A (fr)
MA (1) MA34130B1 (fr)
MX (1) MX2012009689A (fr)
NI (1) NI201200136A (fr)
PE (1) PE20130004A1 (fr)
PH (1) PH12012501684A1 (fr)
PL (1) PL2538924T3 (fr)
SG (1) SG183449A1 (fr)
SI (1) SI2538924T1 (fr)
TN (1) TN2012000363A1 (fr)
TW (1) TW201138767A (fr)
UA (1) UA105285C2 (fr)
UY (1) UY33243A (fr)
WO (1) WO2011104588A2 (fr)
ZA (1) ZA201205559B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014020184B1 (pt) 2012-02-17 2021-11-30 Egis Gyógyszergyár Zrt Preparação farmacêutica que contém anlodipina e ra-mipril
PL227900B1 (pl) 2012-11-15 2018-01-31 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Kompozycja farmaceutyczna zawierająca inhibitor ACE i bloker kanałów wapniowych, sposób jej wytwarzania i jednostka dawkowania zawierająca tę kompozycję
CN104546773B (zh) * 2015-01-30 2018-12-11 华润赛科药业有限责任公司 一种高稳定性苯磺酸氨氯地平片及其制备方法
WO2016207824A2 (fr) * 2015-06-23 2016-12-29 Dr. Reddy's Laboratories Ltd Composition pharmaceutique stable comprenant du ramipril et/ou de l'amlodipine
EP3501502A1 (fr) * 2017-12-20 2019-06-26 Midas Pharma GmbH Compositions pharmaceutiques dosées fixes comprenant de l'amlodipine, du ramipril et de l'atorvastatine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3633496A1 (de) 1986-10-02 1988-04-14 Hoechst Ag Kombination von angiotensin-converting-enzyme-hemmern mit calciumantagonisten sowie deren verwendung in arzneimitteln
JPH11500140A (ja) 1995-03-16 1999-01-06 ファイザー・インコーポレーテッド アムロジピン、アムロジピン塩、もしくはフェロジピンとａｃｅ阻害薬とを含有する組成物
IL148127A0 (en) 1999-08-30 2002-09-12 Aventis Pharma Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
WO2005079772A2 (fr) 2004-02-18 2005-09-01 Sepracor Inc. Combinaison d'(s)-amlodipine et d'un inhibiteur de l'ace, et procedes pour reduire l'hypertension
HUP0401170A2 (en) * 2004-06-10 2006-09-28 Richter Gedeon Vegyeszet Pharmaceutical composition comprising amlodipine besilate and lisinopril dihydrate and process for
JP2008519063A (ja) * 2004-11-05 2008-06-05 キング・ファーマシューティカルズ・リサーチ・アンド・デベロプメント・インコーポレイティッド 安定化ラミプリル組成物及びその製造方法
CN101272791A (zh) * 2005-09-28 2008-09-24 特瓦制药工业有限公司 苯磺酸氨氯地平和盐酸贝那普利的稳定的组合
JP2009508948A (ja) * 2005-09-28 2009-03-05 テバ ファーマシューティカル インダストリーズ リミティド アムロジピンベシレート及びベナゼプリル塩酸塩の安定した組合わせ
TWI399223B (zh) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
US20080096863A1 (en) * 2006-10-19 2008-04-24 Torrent Pharmaceuticals Limited Stable pharmaceutical compositions of calcium channel blocker and an ACE inhibitor

Also Published As

Publication number Publication date
EP2538924A2 (fr) 2013-01-02
CN102781430A (zh) 2012-11-14
JP5719385B2 (ja) 2015-05-20
CN102781430B (zh) 2015-09-09
JP2013520485A (ja) 2013-06-06
AU2010346977A1 (en) 2012-09-13
TW201138767A (en) 2011-11-16
CL2012002341A1 (es) 2012-11-30
ECSP12012121A (es) 2012-09-28
PL2538924T3 (pl) 2014-10-31
CA2790817A1 (fr) 2011-09-01
WO2011104588A2 (fr) 2011-09-01
NI201200136A (es) 2012-10-29
ES2483154T3 (es) 2014-08-05
WO2011104588A3 (fr) 2012-04-19
EP2538924B1 (fr) 2014-05-21
BR112012021203A2 (pt) 2016-05-17
SG183449A1 (en) 2012-09-27
PE20130004A1 (es) 2013-02-01
SI2538924T1 (sl) 2014-09-30
PH12012501684A1 (en) 2012-11-05
TN2012000363A1 (en) 2014-01-30
GT201200248A (es) 2014-05-14
AR080256A1 (es) 2012-03-21
CR20120432A (es) 2012-11-29
MX2012009689A (es) 2012-09-12
ZA201205559B (en) 2013-09-25
UA105285C2 (uk) 2014-04-25
KR20120130761A (ko) 2012-12-03
UY33243A (es) 2011-09-30
US20130146496A1 (en) 2013-06-13
EA201290817A1 (ru) 2013-01-30

Similar Documents

Publication Publication Date Title
MA33463B1 (fr) Compositions à dose pharmaceutique solide fixe comprenant de l'irbésartan et de l'amlodipine, leur préparation et leur application thérapeutique
CY1115652T1 (el) Μορφη δοσολογιας που περιεχει δυο δραστικα φαρμακευτικα συστατικα μειγματος σε διαφορετικες φυσικες μορφες
CY1119817T1 (el) Στερεα μοναδα δοσολογιας διασπωμενη στο στομα που περιεχει συστατικο οιστετρολης
MX2009007784A (es) Composiciones de tiacumicinas estables.
WO2015120110A3 (fr) Nouvelles formulations pharmaceutiques
EA201490477A1 (ru) Фармацевтические составы, содержащие пропиленгликоль-гидрат дапаглифлозина
NO20043367L (no) Oralt farmasoytisk preparat
MX2013014788A (es) Liberacion modificada de 4-metil-3-[[4-(3-piridinl)-2-pirimidinil] -amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil ]-benzamida solubilizada utilizando acidos organicos.
UA110012C2 (uk) Лікарські форми для перорального застосування, що містять ацетат лікарбазепіну
EA201171109A1 (ru) Новая композиция замедленного высвобождения соединений, выбранных из класса миорелаксантов центрального действия
EA201290734A1 (ru) Рифаксимин в форме порошка, способ его получения и композиции контролируемого высвобождения, содержащие указанный рифаксимин, полезные для достижения длительного эффекта
ATE487720T1 (de) 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer
MA34130B1 (fr) Formulations pharmaceutiques solides de ramipril et de bésylate d'amlodipine et leur préparation
PH12015500823A1 (en) Modified release formulations for oprozomib
EA201500513A1 (ru) Продукт сомикронизации, включающий ацетат улипристала
EP2504331A4 (fr) Composé, certaines nouvelles formes de celui-ci, compositions pharmaceutiques de celui-ci et procédés de préparation et d'utilisation
EA201170583A1 (ru) Новая композиция для лечения эссенциальной тромбоцитемии
ATE460934T1 (de) Pharmazeutische zubereitungen von ciprofloxacin
MX2017005163A (es) Composiciones de liberación prolongada de onapristona y métodos.
TR201803451T4 (tr) Olmesartan formülasyonlari.
MA38093A1 (fr) Formulations à libération modifiée pour l'oprozomib
IN2013MU02286A (fr)